4547:TYO
Kissei Pharmaceutical Co Ltd
¥3,785.00
arrow_downward
-0.39%(-15.00) 1D
Oct 19, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
¥3,845
High
¥3,850
Low
¥3,775
Mkt. cap
176.16B
Avg. vol.
74.89K
Volume
84.80K
Dividend
3.17%
Quarterly dividend
¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.22
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥337
Shares outstanding
46.72M
No. of employees
2K
Open
¥3,845
High
¥3,850
Low
¥3,775
Mkt. cap
176.16B
Avg. vol.
74.89K
Volume
84.80K
Dividend
3.17%
Quarterly dividend
¥30
Ex-dividend date
Sep 29, 2026
P/E ratio
11.22
52-wk high
¥5,040
52-wk low
¥3,500
EPS
¥337
Shares outstanding
46.72M
No. of employees
2K
News stories
From web sources and news partners
FXStreet
·
1 hour ago
The S&P 500 is on a dangerous path
bloomingbit
·
33 minutes ago
U.S. Stocks Turn Higher; Nasdaq Up 1.36%
www.marketscreener.com
·
1 hour ago
FactSet Research : Are “Magnificent 7” Companies Still Top Contributors to S&P 500 Earnings Growth for Q3
TradingView
·
3 hours ago
The Dow Jones Index Opens 0.08% Lower
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79K
FoundedAug 9, 1946
HeadquartersMatsumoto, Nagano, Japan
SectorPharmaceutical industry
Websitekissei.co.jp